ArticlePediatric surgery international2026
A novel compound heterozygous variant in DNAH2: preliminary evidence of a potential genetic modifier for persistent cloaca in a Chinese family.
Article in Pediatric surgery international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPersistent cloaca (PC), the most severe subtype of congenital anorectal malformations (ARMs) in female infants with an incidence of 1/50,000 live births, has poorly understood etiology.
methodsThe study enrolled 12 Chinese PC patients (4 trio families, 8 unrelated individuals), performed whole exome sequencing (WES) via the CG Black Bird platform, extracted genomic DNA from peripheral blood and cryopreserved surgical specimens, annotated variants using databases (dbSNP, gnomAD) and tools (SIFT/PolyPhen2), assessed pathogenicity by 2015 ACMG/AMP Guidelines, and validated via Sanger sequencing. We generated Dnah2⁻/⁻ mice and silenced DNAH2 in human mesenchymal stem cells (hMSCs) to detect SHH pathway proteins.
resultsA novel DNAH2 compound heterozygous variant (p.Ser312Thr, p.Arg573Cys, inherited from asymptomatic parents) was identified in one trio, both classified as Variants of Unknown Significance (VUS). Dnah2⁻/⁻ mice showed vaginal atresia and features consistent with ciliary dysfunction; DNAH2 silencing in hMSCs reduced Smo (53.1%), Gli2 (66.4%).
conclusionThe first report of the DNAH2 compound heterozygous variant in Chinese PC patients suggests DNAH2 should be considered a candidate susceptibility gene for PC (limited by small sample, conflicting evidence, model flaws), providing a preliminary basis for cilia-associated gene research in PC.
Indexed as
Identifiers
42228139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.